Indian Move Sparks Industry Worry Over Wider Price Controls
This article was originally published in PharmAsia News
Executive Summary
A week after India’s drug pricing watchdog slashed the prices of 108 formulations in the diabetes and cardiovascular areas, a debate has kicked off in which the industry is unequivocally questioning the government step to tweak policy while health experts are supporting the move. The government is pointing to a case of “severe market failure” but the industry says the price controls may in fact jeopardize the availability of drugs to patients.